FDA approves 4-week dosing for BMS cancer drug

Mar 06, 2018

The U.S. Food and Drug Administration has approved a four-week dosing schedule for Bristol-Myers Squibb's cancer drug, Opdivo.

 A two-week dosing had already been approved previously and now BMS have announced that the drug is also approved for 30-minute infusions, down from the previous 60-minute infusions.

While the PD-1 inhibitor Opdivo has rivals from Merck and Roche, it is now the only inhibitor to offer four-week dosing.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments